Establishment Labs Welcomes New SVP and Chief Financial Officer

Establishment Labs Holdings Inc. is reshuffling its executive leadership, promoting Chief Financial Officer (CFO) Raj Denhoy to senior vice president, Global Strategy, and appointing Cassandra “Sandra” Harris to fill his position (senior vice president/CFO).

“Over the past few years, we have been focused on driving efficient execution and scalability. With the company well-positioned for its next chapter of growth, we are creating additional leadership capacity to maintain operational momentum while managing several initiatives that require strong leadership and oversight,” Establishment Labs CEO Peter Caldini stated. “Raj’s move into a dedicated strategy role and Sandra’s appointment as CFO reflect our confidence in the strength and future of our business. These changes will help us to accelerate initiatives that drive highly profitable growth in the future.”

Harris served most recently worked as senior vice president, Finance, and CFO of Genesco Inc., where she led all core financial functions and supported profitability and capital allocation initiatives. Previously, she was CFO of Artisan Design Group, where she strengthened financial controls. From 2019 to 2022, Harris was CFO and chief operating officer of Tupperware Brands, where she led a comprehensive turnaround focused on cost reduction, liquidity improvement, leverage reduction, and the transition to an omnichannel, digitally-enabled business model.

“As a recent breast cancer survivor, I could not be more passionate about the mission of Establishment Labs,” Harris said. “The Motiva portfolio of products is absolutely game-changing for the one in eight women who develop breast cancer. Being able to contribute to our commercialization and continued innovation is a real opportunity to make a difference. My goal is that every woman that faces what I faced can have a true aesthetic breast reconstruction without compromise. Giving women choices through innovation and superior technology expands the market and creates the kind of highly profitable growth that allows us to continue our mission-driven business.”

Denhoy was CFO from 2021 to 2026, having joined the company from Jefferies Group LLC, where he was a managing director and led the U.S. medical device research team for 11 years, including coverage of Establishment Labs. He covered the medical device industry as an equity research analyst for more than 20 years. Denhoy earned a bachelor’s degree in biology from UC Berkeley, a master’s degree in physiology from Georgetown University, and an MBA from Cornell University.

In his new role, Denhoy will focus on key growth accelerators and strategic initiatives critical to the company’s growth, bringing deep company and industry experience as well as a clear strategic perspective. Denhoy will also oversee a smooth transition of CFO responsibilities to Harris.

Establishment Labs Holdings Inc. is a global medical device company striving to improve women’s health and wellness in breast aesthetics and reconstruction through science, engineering, and technology. The company offers solutions for breast health, breast aesthetics, and breast reconstruction in more than 100 countries. With over 4 million Motiva devices delivered to plastic and reconstructive surgeons since 2010, the company claims its products have created a new standard for safety and patient satisfaction. The company’s minimally invasive platform consists of Mia Femtech for breast harmonization, and Preservé, a breast tissue preserving technology for breast augmentation, revision augmentation, and mastopexy augmentation. GEM is a next-generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB-approved pivotal study. The Motiva Flora tissue expander is used to improve outcomes in breast reconstruction after breast cancer and is the world’s only regulatory-approved expander with an integrated port using radio-frequency technology that is MRI conditional. Zensor is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zenº, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by more than 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer-reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica, compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820.